A Phase II, Randomized, Double-Blind, Active-Controlled

Project: Research project

Project Details

Description

A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 (200 mg BID) for 10 days
StatusFinished
Effective start/end date6/17/1412/31/15

Funding

  • Summit plc